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Libman–Sacks endocarditis, first discovered in 1924, is a cardiac manifestation of systemic lupus erythematosus
(SLE). Valvular involvement has been associated with SLE and antiphospholipid syndrome (APS). Mitral valve,
especially its posterior leaflet, is most commonly involved.
We report a case of a 34 year old woman with antiphospholipid antibody syndrome and SLE, who presented
with mitral valve regurgitation. The patient underwent a prosthetic mitral valve replacement, with no followup com-
plications.
We suggest mechanical valve replacement employment in the management of mitral regurgitation in Libman–
Sacks endocarditis, in view of the recent medical literature and our own case report.
 2015 The Authors. Production and hosting by Elsevier B.V. on behalf of King Saud University. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Libman–Sacks endocarditis, first described in1924, is the most characteristic cardiac mani-
festation of systemic lupus erythematosus (SLE),
although the association between Libman–Sacks
endocarditis and antiphospholipid syndrome
(APS) was first discovered in 1985 [1,2]. Mitral
valve, especially its posterior leaflet, is most
frequently affected [3]. Transthoracic andtransesophageal echocardiography have shown
that valvular involvement is greater in SLE
patients who have antiphospholipid antibodies
and severely symptomatic individuals may
require surgery [4].Case report
We report a case of a 34-year-old woman, with a
known diagnosis of APS and SLE for 10 years, who
presented with a 6-month history of progressingheCCBY-
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MITRAL VALVE REPLACEMENT OR REPAIRdyspnea. Other comorbidities included hyperten-
sion and hypothyroidism. Examination revealed
tachycardia and a pan-systolic murmur.
A transesophageal echocardiogram showed a
severely dilated left atrium with normal left ven-
tricular systolic function, severe mitral regurgita-
tion with sessile vegetations on the posterior
leaflet, a left ventricular end-diastolic diameter
of 60 mm, and an ejection fraction of 60%. Mild tri-
cuspid regurgitation was also reported. The
patient was scheduled for valve replacement.
In the operating room, the mitral valve was
exposed with a superior septal approach (Fig. 1).
The anterior leaflet was fully excised, while the
posterior leaflet with its vegetations was partially
excised. A 29 mm carbomedics mechanical valve
was placed.
Histopathological examination revealed archi-
tectural distortion of the valve leaflets with myx-
oid degenerative changes, characteristic of
Libman–Sacks endocarditis.
No intraoperative or postoperative complica-
tions were encountered. A 6-day postoperative
chest radiograph showed proper position and an
echocardiogram revealed normal function of the
prosthesis. After 7 days the patient was dis-Figure 1. Mitral valve of the pacharged on long-term anticoagulation. Follow-up
after more than 1 year showed no complications,
including any thromboembolic events.Discussion
Libman–Sacks endocarditis is characterized by
mulberry-like clusters of verrucous lesions on
the valves, most commonly the mitral valve, fol-
lowed by the aortic valve. They exhibit heteroge-
neous echogenicity and no independent
movement and can lead to complications includ-
ing valve regurgitation, stenosis, infective endo-
carditis, and thromboembolic events [4].
Histopathology reveals inflammation with cell
proliferation, degeneration, mononuclear infil-
trates, and fibrin deposits [3,4]. The natural history
of the disease suggests progression over time with
deterioration of the lesions [4,5].
Theoriginof these lesions is very closely related to
the presence of antiphospholipid antibodies, hence
the associationwithAPS and SLE [3]. Antiphospho-
lipid antibodies interfere with coagulation profiles
of the patients affecting the partial thromboplastin
time and thrombin time; hence the risk oftient showing vegetations.
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require long-term anticoagulation [1,6].
The literature reports a wide range of percent-
ages for valve involvement with SLE, ranging
from 11–74%, depending on the diagnostic tech-
nique. Transesophageal echocardiography is the
best diagnostic modality established so far, being
superior to the transthoracic echocardiograph
[3,4].
Treatment options can be broadly divided into
medical and surgical. Medical management is
reserved for hemodynamically stable patients,
where a trial of steroids may be given. However,
steroids in themselves may lead to early fibrosis
later [3].
There is controversy in literature regarding the
use of mitral valve repair versus mitral valve
replacement for management of mitral regurgita-
tion in Libman–Sacks endocarditis. Mitral valve
replacement may be used for various reasons
including lesser mortality, low costs, better ven-
tricular function, a lower need of anticoagulation,
and lower complications. Valve replacement offers
low recurrence rates compared with repair and
may be preferred for more symptomatic and
severe cases. It is generally not recommended
for women of child-bearing age as they
would have to be put on anticoagulation therapy,
which is avoided with repair. However, many
believe that the patient may be ultimately put on
anticoagulants anyway for the underlying disease
itself.
A successful case of mitral valve replacement for
mitral regurgitation in a patient with SLE was first
reported in 1974 by Myerowitz et al. [7]. Hakim
et al. [8] reported five such cases with mitral valve
regurgitation, of which three underwent pros-
thetic valve replacement, while two had mitral
valve repair. Long-term follow up revealed norecurrence in replacement but one of the two
cases of repair relapsed, ultimately requiring
valve replacement.
Bouma et al. [4], after a review of literature from
1974 to 2010, preferred mitral valve replacement
over repair in most situations.
One issue with valve repair is that when cardiac
valvular replacement is done, anticoagulation is
mandatory.
Although we are reporting a single case of mitral
regurgitation in SLE, in view of the literature and
according to our experience, we suggest mitral
regurgitation in Libman–Sacks endocarditis to be
treated with a mechanical prosthetic mitral valve.
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